These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31002021)

  • 1. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study.
    Solidoro P; Patrucco F; de Blasio F; Brussino L; Bellocchia M; Dassetto D; Pivetta E; Riccio A; Heffler E; Canonica W; Rolla G; Bucca C
    Ther Adv Respir Dis; 2019; 13():1753466619841274. PubMed ID: 31002021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors reducing omalizumab response in severe asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Santus P; Perrella A; Paggiaro PL
    Eur J Intern Med; 2018 Jun; 52():78-85. PubMed ID: 29395935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.
    Sposato B; Scalese M; Ricci A; Rogliani P; Paggiaro P;
    Clin Respir J; 2021 Feb; 15(2):237-243. PubMed ID: 33400385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
    AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA.
    Hanania NA; Fortis S; Haselkorn T; Gupta S; Mumneh N; Yoo B; Holweg CTJ; Chipps BE
    J Allergy Clin Immunol Pract; 2022 Jan; 10(1):222-228. PubMed ID: 34419680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
    Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
    J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
    [No Abstract]   [Full Text] [Related]  

  • 15. Small, Prospective, Observational, Pilot Study in Patients with Severe Asthma after Discontinuation of Omalizumab Treatment.
    Krčmová I; Novosad J; Malá E; Krejsek J
    Clin Ther; 2018 Nov; 40(11):1942-1953. PubMed ID: 30391022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients.
    Tamagaki G; Kanazawa H; Hirata K
    Pulm Pharmacol Ther; 2012 Dec; 25(6):478-82. PubMed ID: 22982562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility.
    Zhao H; Li R; Lv Y; Dong H; Yao L; Wu Y; Xiao G; Cai S
    Clin Respir J; 2017 May; 11(3):328-336. PubMed ID: 26077165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
    Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
    Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
    Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β
    Hoshino M; Akitsu K; Ohtawa J
    J Asthma; 2019 Sep; 56(9):995-1003. PubMed ID: 30212239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.